Drug Interactions between rifabutin and troleandomycin
This report displays the potential drug interactions for the following 2 drugs:
- rifabutin
- troleandomycin
Interactions between your drugs
troleandomycin rifabutin
Applies to: troleandomycin and rifabutin
GENERALLY AVOID: The coadministration of clarithromycin and rifabutin at normally recommended dosages has been reported to have resulted in significantly altered pharmacokinetics for both drugs. In a study of 34 clinically stable subjects with advanced HIV infection (CD4 less than 200 cells/mm3), the addition of rifabutin in patients stabilized on clarithromycin therapy slowly decreased the clarithromycin area under the plasma concentration-time curve (AUC) and peak plasma concentration (Cmax) up to an average of 44% and 41%, respectively, at the end of 4 weeks of combination therapy. In patients stabilized on rifabutin therapy, the addition of clarithromycin significantly increased rifabutin AUC and Cmax after the first dose. After 4 weeks, average increases of 99% and 69%, respectively, were reported. This bidirectional interaction is consistent with rifabutin's cumulative inducing effect over time on the CYP450 enzymatic pathway as well as clarithromycin's immediate inhibiting effect on the pathway. In the study, the combination was tolerated by more than 90% of the patients. However, 66% of them experienced gastrointestinal problems including nausea, vomiting and diarrhea. An increased incidence of uveitis has also been reported with this combination. In addition, the combination of clarithromycin and rifampin 600 mg/day (with multiple other drugs) decreased clarithromycin serum levels by approximately 90%. Other macrolide antibiotics may interact in a similar manner with rifamycins.
MANAGEMENT: Some authorities recommend that this combination be avoided since it may result in decreased efficacy of the macrolide and increased rifamycin toxicity (e.g., neutropenia, uveitis). If coadministration cannot be avoided, patients should be monitored for rifamycin toxicity such as leukopenia, uveitis, arthralgias and skin discoloration. Some authorities recommend discontinuing erythromycin during and two weeks after treatment with CYP 450 3A4 inducers. Further dosage adjustments may be necessary.
References (14)
- Wallace RJ, Brown BA, Griffith DE, Girard W, Tanaka K (1995) "Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium -M.intracellulare infection." J Infect Dis, 171, p. 747-50
- Hafner R, Bethel J, Power M, et al. (1998) "Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers." Antimicrob Agents Chemother, 42, p. 631-9
- von Rosenstiel NA, Adam D (1995) "Macrolide antibacterials. Drug interactions of clinical significance." Drug Saf, 13, p. 105-22
- Benson CA, Williams PL, Cohn DL, Becker S, Hojczyk P, Nevin T, Korvick JA, Heifets L, Child CC, Lederman MM, Reichman RC, (2000) "Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: A randomized, double-blind, placebo-controlled trial." J Infec Dis, 181, p. 1289-97
- Benson CA, Williams PL, Currier JS, et al. (2003) "A Prospective, Randomized Trial Examining the Efficacy and Safety of Clarithromycin in Combination with Ethambutol, Rifabutin, or Both for the Treatment of Disseminated Mycobacterium avium Complex Disease in Persons with Acquired Immunodeficiency Syndrome" Clin Infect Dis, 37, p. 1234-43
- Jordan MK, Polis MA, Kelly G, Narang PK, Masur H, Piscitelli SC (2000) "Effects of fluconazole and clarithromycin on rifabutin and 25-O-desacetylrifabutin pharmacokinetics." Antimicrob Agents Chemother, 44, p. 2170-72
- Apseloff G, Foulds G, LaBoy-Goral L, Willavize S, Vincent J (1998) "Comparison of azithromycin and clarithromycin in their interactions with rifabutin in healthy volunteers." J Clin Pharmacol, 38, p. 830-5
- Griffith DE, Brown BA, Girard WM, Wallace RJ Jr (1995) "Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease." Clin Infect Dis, 21, p. 594-8
- (2020) "Product Information. Clarithromycin ER (clarithromycin)." Actavis U.S. (Purepac Pharmaceutical Company)
- (2023) "Product Information. Erythromycin Ethylsuccinate (erythromycin)." Zydus Pharmaceuticals (USA) Inc
- (2023) "Product Information. Eryc (ERYthromycin)." Mayne Pharma International Pty Ltd
- (2024) "Product Information. Erythrocin (erythromycin)." Advanz Pharma
- (2024) "Product Information. Mycobutin (rifabutin)." Pfizer U.S. Pharmaceuticals Group
- (2023) "Product Information. Mycobutin (rifabutin)." Pfizer Canada Inc
Drug and food interactions
No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.